NYSE - Delayed Quote
USD
Hims & Hers Health, Inc. (HIMS)
27.41
+0.24
(+0.88%)
At close: May 1 at 4:00:05 PM EDT
27.42
+0.01
(+0.04%)
After hours: May 1 at 7:59:13 PM EDT
Trade HIMS on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for HIMS
- Previous Close
27.17 - Open
27.29 - Bid --
- Ask --
- Day's Range
26.93 - 27.77 - 52 Week Range
13.74 - 70.43 - Volume
14,284,516 - Avg. Volume
39,544,812 - Market Cap (intraday)
6.334B - Beta (5Y Monthly) 2.32
- PE Ratio (TTM)
53.75 - EPS (TTM)
0.51 - Earnings Date May 11, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
26.25
Recent News: HIMS
View More
Performance Overview: HIMS
Trailing total returns as of 5/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
HIMS
15.58%
S&P 500 (^GSPC)
5.62%
1-Year Return
HIMS
24.20%
S&P 500 (^GSPC)
29.01%
3-Year Return
HIMS
128.04%
S&P 500 (^GSPC)
73.47%
5-Year Return
HIMS
121.41%
S&P 500 (^GSPC)
72.92%
Earnings Trends: HIMS
View MoreAnalyst Insights: HIMS
View MoreStatistics: HIMS
View MoreValuation Measures
As of 5/1/2026
-
Market Cap
6.33B
-
Enterprise Value
6.88B
-
Trailing P/E
53.75
-
Forward P/E
64.52
-
PEG Ratio (5yr expected)
2.36
-
Price/Sales (ttm)
3.01
-
Price/Book (mrq)
11.71
-
Enterprise Value/Revenue
2.93
-
Enterprise Value/EBITDA
42.95
Financial Highlights
Profitability and Income Statement
-
Profit Margin
5.47%
-
Return on Assets (ttm)
5.29%
-
Return on Equity (ttm)
25.23%
-
Revenue (ttm)
2.35B
-
Net Income Avi to Common (ttm)
128.37M
-
Diluted EPS (ttm)
0.51
Balance Sheet and Cash Flow
-
Total Cash (mrq)
577.49M
-
Total Debt/Equity (mrq)
207.16%
-
Levered Free Cash Flow (ttm)
110.51M
Compare To: HIMS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
27.41
+0.88%
Mkt Cap
6.334B
Industry
Drug Manufacturers—Specialty & Generic
29.12
-0.34%
Mkt Cap
14.4B
Industry
Drug Manufacturers—Specialty & Generic
4.2000
+2.44%
Mkt Cap
521.995M
Industry
Drug Manufacturers—Specialty & Generic
34.95
-0.34%
Mkt Cap
40.697B
Industry
Drug Manufacturers—Specialty & Generic
6.16
-1.28%
Mkt Cap
736.762M
Industry
Drug Manufacturers—Specialty & Generic
1.1300
+1.80%
Mkt Cap
507.461M
Industry
Drug Manufacturers—Specialty & Generic
2.0700
+0.49%
Mkt Cap
1.983M
Industry
Drug Manufacturers—Specialty & Generic
3.4800
+1.16%
Mkt Cap
205.761M
Industry
Drug Manufacturers—Specialty & Generic
Company Insights: HIMS
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports: HIMS
View More-
Lowering target price to $27.00
HIMS & HERS HEALTH INC has an Investment Rating of HOLD; a target price of $27.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target -
With Legal Overhang Behind, Hims Looks To Drive Growth via Novo Partnership and International Push
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
RatingPrice Target -
Raising target price to $28.00
HIMS & HERS HEALTH INC has an Investment Rating of HOLD; a target price of $28.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target -
With Legal Overhang Behind, Hims Looks To Drive Growth via Novo Partnership and International Push
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
RatingPrice Target
